A modular nanotransporter (MNT) carrying the sequence of an antibody-like molecule, anti-c-Myc nanobody, was synthesized and characterized. It was demonstrated that the created MNT is able to interact with the target protein, c-Myc oncogene, with a dissociation constant of 46 ± 14 nM, internalize into target cells, change Myc-dependent expression, and exert an antiproliferative effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1134/S1607672923700114 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases.
Front Immunol
November 2024
Mozart Therapeutics, Seattle, WA, United States.
Article Synopsis
- - Regulatory CD8 T cells (CD8 Treg) usually help control harmful CD4 T cells, but in autoimmune diseases, they often fail, partly due to inhibitory receptors that limit their activation.
- - A new bispecific antibody called MTX-101 targets these inhibitory receptors and CD8 T cells to enhance the ability of CD8 Treg to eliminate pathogenic CD4 T cells in various experimental models.
- - In studies, MTX-101 improved CD8 Treg activity, reduced harmful CD4 T cell expansion, and protected tissues from damage without triggering excessive inflammation, showing promise for treating autoimmune disorders.
Direct recognition of an intact foreign protein by an αβ T cell receptor.
Nat Commun
October 2024
Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
αβ T cell receptors (αβTCRs) co-recognise antigens when bound to Major Histocompatibility Complex (MHC) or MHC class I-like molecules. Additionally, some αβTCRs can bind non-MHC molecules, but how much intact antigen reactivities are achieved remains unknown. Here, we identify an αβ T cell clone that directly recognises the intact foreign protein, R-phycoerythrin (PE), a multimeric (αβ)γ protein complex.
View Article and Find Full Text PDFA First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.
Clin Cancer Res
September 2024
Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Purpose: 4-1BB (CD137) is a costimulatory immune receptor expressed on activated T cells, activated B cells, natural killer cells and tumor-infiltrating lymphocytes, making it a promising target for cancer immunotherapy. Cinrebafusp alfa, a monoclonal antibody-like bispecific protein targeting HER2 and 4-1BB, aims to localize 4-1BB activation to HER2-positive tumors. This study evaluated the safety, tolerability, and preliminary efficacy of cinrebafusp alfa in patients with previously treated HER2-positive malignancies.
View Article and Find Full Text PDFIL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release.
MAbs
August 2024
R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
T cell engagers (TCEs) are becoming an integral class of biological therapeutic owing to their highly potent ability to eradicate cancer cells. Nevertheless, the widespread utility of classical CD3-targeted TCEs has been limited by narrow therapeutic index (TI) linked to systemic CD4+ T cell activation and aberrant cytokine release. One attractive approach to circumvent the systemic activation of pan CD3+ T cells and reduce the risk of cytokine release syndrome is to redirect specific subsets of T cells.
View Article and Find Full Text PDFA broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites.
Nat Commun
August 2024
Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Sciences, La Trobe University, Victoria, 3086, Australia.
Apical membrane antigen-1 (AMA1) is a conserved malarial vaccine candidate essential for the formation of tight junctions with the rhoptry neck protein (RON) complex, enabling Plasmodium parasites to invade human erythrocytes, hepatocytes, and mosquito salivary glands. Despite its critical role, extensive surface polymorphisms in AMA1 have led to strain-specific protection, limiting the success of AMA1-based interventions beyond initial clinical trials. Here, we identify an i-body, a humanised single-domain antibody-like molecule that recognises a conserved pan-species conformational epitope in AMA1 with low nanomolar affinity and inhibits the binding of the RON2 ligand to AMA1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!